Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2019-11-07. Its lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. Its second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The firm's new lead program is the Investigator-sponsored Phase I/II trial of a pan-NOS Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer.
Follow-Up Questions
Qui est le CEO de Galera Therapeutics Inc ?
Dr. J. Mel Sorensen est le Chairman of the Board de Galera Therapeutics Inc, il a rejoint l'entreprise depuis 2012.
Quelle est la performance du prix de l'action GRTX ?
Le prix actuel de GRTX est de $0.02, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Galera Therapeutics Inc ?
Galera Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Galera Therapeutics Inc ?
La capitalisation boursière actuelle de Galera Therapeutics Inc est de $1.5M
Est-ce que Galera Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Galera Therapeutics Inc, y compris 0 achat fort, 0 achat, 4 maintien, 1 vente et 0 vente forte
